Edwin C. Reisz, Chief Administrative Officer at Aveanna Healthcare Holdings, Inc. (NASDAQ: AVAH), executed three sales of company stock between February 17 and February 19, 2026, disposing of a total of 161,043 shares. The aggregate proceeds from those transactions were $1.19 million.
The first transaction, carried out on February 17, involved 42,057 shares sold at a weighted average price of $7.6451, with individual trade prices spanning $7.47 to $7.97. On February 18, Reisz sold 59,217 shares at an average price of $7.3829; the reported price range for that session was $7.175 to $7.53. The final block, on February 19, consisted of 60,769 shares sold at a weighted average price of $7.2082, with trade prices between $7.06 and $7.29.
Company stock is quoted at $7.42, reflecting a 6.4% decline over the trailing week, though shares have appreciated 54% over the past year. InvestingPro analysis referenced in company reporting indicates the stock appears undervalued at current levels, with further detail available in that platform’s Pro Research Report.
The insider sales were reported as necessary to satisfy tax obligations arising from the vesting of equity awards. Following the three transactions, Reisz is recorded as holding 1,447,057 shares of Aveanna Healthcare, representing roughly 0.9% of the company’s outstanding shares.
Separately, Aveanna updated its financial guidance for fiscal year 2025 and provided initial projections for fiscal 2026. For 2025, the company now expects revenue in a range between $2.425 billion and $2.445 billion, raised from a prior outlook of more than $2.375 billion. For fiscal 2026, Aveanna supplied preliminary net income guidance of between $181 million and $220 million.
The revised outlook and initial guidance prompted multiple analyst firms to adjust their valuations and ratings. UBS increased its price target for Aveanna to $10.00, citing the improved 2025 revenue and adjusted EBITDA guidance. RBC Capital raised its price target to $11.00 after Aveanna issued 2026 guidance that exceeded consensus expectations. Raymond James lifted its price target to $13.00, attributing the raise in part to a favorable Home Health Final Rule and a detailed review of the company’s debt-paydown timing, which supported higher EBITDA estimates for 2026 and 2027. In addition, William Blair initiated coverage of Aveanna with an Outperform rating, noting the company’s position as a leading private duty nursing provider.
Taken together, the insider sale to meet tax obligations occurred in the context of updated company guidance and multiple positive analyst responses. The reported stock transactions and the company’s revised forward-looking figures are disclosed in regulatory filings and company statements covering the February 17-19, 2026, period.